SINGLE-CELL DNA ANALYSIS OF MUTATIONAL HETEROGENEITY IN ACUTE MYELOID LEUKEMIA TUMORS WITH HIGH-THROUGHPUT DROPLET MICROFLUIDICS

EHA Learning Center, Dennis Eastburn, 214633

INFLAMED BM-MSCS HIGHLY ATTRACT TEL-AML1+ PRE-LEUKEMIC CELLS AND PROVIDE A SUSTAINING NICHE FOR THEIR EMERGENCE

EHA Learning Center, Linda Beneforti, 215233

COHESIN GENES MUTATIONS IN ACUTE LYMPHOBLASTIC LEUKEMIA

EHA Learning Center, Grazia Fazio, 215248

EVALUATION OF SAMPLE QUALITY AND CREATION OF DATABASES FOR FOLLOW-UP ASSESSMENT OF BLAST INFILTRATION AT DAY +15 IN CHILDHOOD B CELL ACUTE LYMPHOBLASTIC LEUKEMIA.

EHA Learning Center, Pablo Manresa Manresa, 215249

GENETIC ALTERATIONS OF T-CELL ACUTE LYMPHOBLASTIC LEUKEMIA IN TAIWAN: A COMPARISON BETWEEN PEDIATRIC AND ADULT COHORTS

EHA Learning Center, Ying-Jung Huang, 215250

THE RISK OF DEVELOPING HEPATIC TOXICITY FROM PEGYLATED-ASPARAGINASE IN ADULT ACUTE LYMPHOBLASTIC LEUKEMIA PATIENTS IS HIGHLY AFFECTED BY CONCOMITANT MEDICATIONS

EHA Learning Center, Paola Minetto, 215265

CELL OF ORIGIN INFLUENCES DISEASE AGGRESSIVENESS AND CHEMOTHERAPY RESISTANCE IN A MOUSE MODEL OF MLL-AF9 REARRANGED ACUTE MYELOID LEUKEMIA

EHA Learning Center, Chi Nguyen, 215266

PLASMA PROTEOME IN PATIENTS WITH LEUKEMIA AND LYMPHOMA REVEALS MAJOR DIFFERENCES RELATED TO HEMOSTASIS, INFLAMMATION AND STROMA

EHA Learning Center, Anna Eriksson, 215267

TARGETED THERAPY FOR AML EXPRESSING SOMATIC OR GERMLINE MUTATION IN RUNX1

EHA Learning Center, Kapil Bhalla, 215281

DECIPHERING THE GENETIC LANDSCAPE OF ACUTE MYELOID LEUKEMIA WITH COMPLEX KARYOTYPE BY TRANSCRIPTOME ANALYSIS USING RNA SEQUENCING

EHA Learning Center, Frank Rücker, 215282

PHOSPHO-PROFILING LINKING AML-BIOLOGY AND RESPONSE PREDICTION IN PEDIATRIC MYELOID LEUKEMIA

EHA Learning Center, Michaela Prchal-Murphy, 215283

MOLECULAR ABNORMALITIES IN THERAPY-RELATED ACUTE MYELOID LEUKEMIAS

EHA Learning Center, Gueorgui Balatzenko, 215298

CD123 REDIRECTED NK92 CELLS FOR ACUTE MYELOID LEUKEMIA

EHA Learning Center, Li Zhou, 215299

THE DIFFERENTIAL EXPRESSION OF DNMT3A SPLICE VARIANTS AND THEIR PROGNOSTIC RELEVANCE IN ACUTE MYELOID LEUKEMIA

EHA Learning Center, Stefanie Beinicke, 215300

ADMINISTRATION OF BPX-501 CELLS FOLLOWING ALPHA/BETA T-CELL AND B-CELL-DEPLETED HLA HAPLOIDENTICAL HSCT (HAPLO-HSCT) IN CHILDREN WITH ACUTE MYELOGENOUS LEUKEMIA

EHA Learning Center, Neena Kapoor, 215314

COMPARISON BETWEEN MULTIPARAMETRIC FLOW CYTOMETRY AND RT-QPCR ASSAY IN EVALUATING MINIMAL RESIDUAL DISEASE BEFORE ALLOGENEIC STEM CELL TRANSPLANTATION IN NPM1 ACUTE MYELOID LEUKEMIA

EHA Learning Center, Chiara Caprioli, 215315

MRD STATUS AT TRANSPLANTATION IN SECOND OR THIRD CR IS THE STRONGEST FACTOR AFFECTING THE PROBABILITY OF RELAPSE IN AML PATIENTS

EHA Learning Center, Fabio Guolo, 215316

TYROSINE KINASE INHIBITORS (TKI) IN RELAPSED/REFRACTORY (RR) PATIENTS WITH FLT3-ITD POSITIVE ACUTE MYELOID LEUKEMIA (AML) CONFER BETTER SURVIVAL THAN CHEMOTHERAPY, DUE TO A BETTER SAFETY PROFILE.

EHA Learning Center, Giovanni Marconi, 215330

ADDITION OF BORTEZOMIB TO AML-LIKE TREATMENT FOLLOWED BY NMA ALLO-SCT IN PATIENTS WITH BLASTIC PLASMACYTOID DENDRITIC CELL NEOPLASM

EHA Learning Center, Elisabeth Tolley, 215331

BLAST TRANSFORMATION IN MYELODYSPLASTIC AND MYELOPROLIFERATIVE NEOPLASMS - SIMILARITIES AND DIFFERENCES - A REVIEW OF 100 CASES

EHA Learning Center, Milan Jagurinoski, 215332

EXCELLENT OUTCOMES OF OLDER PATIENTS WITH PCNSL USING R-MPV/ARA-C IMMUNOCHEMOTHERAPY WITHOUT WHOLE BRAIN RADIOTHERAPY (WBRT)

EHA Learning Center, Gareth Gregory, 215346

FIRST REPORT ON A SUCCESSFUL SCREENING PROGRAM FOR MYC REARRANGEMENTS AND A PROSPECTIVE CLINICAL TRIAL BASED ON MYC REARRANGEMENT IN NEWLY DIAGNOSED DLBCL PATIENTS IN THE NETHERLANDS

EHA Learning Center, Martine Chamuleau, 215347

A NOVEL IMMUNOHISTOCHEMICAL PROGNOSTIC SCORE BASED ON MYC, BCL2 AND BCL6 EXPRESSION IN DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL): RETROSPECTIVE ANALYSIS OF DE NOVO DLBCL TREATED WITH RITUXIMAB-CHOP

EHA Learning Center, Mattia Novo, 215348

THE IMPACT OF DIFFERENT IMMUNOCHEMOTHERAPY REGIMENS ON SURVIVAL OUTCOMES IN 131 NEWLY DIAGNOSED PRIMARY MEDIASTINAL LARGE B-CELL LYMPHOMA

EHA Learning Center, Gayane Tumyan, 215362

TREATMENT OF TRAUMATIC BLEEDS WITH RECOMBINANT FACTOR XIII-A2 IN PATIENTS WITH CONGENITAL FXIII-A SUBUNIT DEFICIENCY: RESULTS FROM THE MENTOR™6 STUDY

EHA Learning Center, Jolanta Klovaite, 215363

BEVACIZUMAB SIGNIFICANTLY IMPROVES SEVERE EPISTAXIS IN HEREDITARY HEMORRHAGIC TELANGIECTASIA

EHA Learning Center, Silva ZUPANCIC SALEK, 215364

PHASE 2 STUDY OF X4P-001: A TARGETED ORAL THERAPY FOR PATIENTS WITH WHIM SYNDROME

EHA Learning Center, David Dale, 215378

SCREENING FOR TELOMERE DISEASE IS IMPORTANT TO IMPROVE THE OUTCOME OF HSCT IN PEDIATRIC PATIENTS SUFFERING FROM SEVERE APLASTIC ANEMIA.

EHA Learning Center, Iris Nederlof, 215379

RESULTS OF HEMATOPOIETIC STEM CELLS TRANSPLANTATION IN CONGENITAL BONE MARROW FAILURE SYNDROMES: SINGLE CENTER EXPERIENCE WITH FOCUS ON TCR ΑΒ+/CD19+ DEPLETION

EHA Learning Center, Zhanna Shekhovtsova, 215380

DEVELOPMENT OF SELECTIVE CASEIN KINASE 1 DELTA/EPSILON INHIBITORS FOR CANCER THERAPY

EHA Learning Center, Michaela Gregorova, 215394

NEXT-GENERATION SEQUENCING AND CRISPR/CAS9 APPLICATION TO ELUCIDATE THE IMPLICATIONS OF TP53 MUTATIONS IN DEL(13Q) CHRONIC LYMPHOCYTIC LEUKEMIA

EHA Learning Center, Miguel Quijada Alamo, 215396

ENCYCLOPEDIA OF CLL SUBSETS: AN ONLINE KNOWLEDGEBASE FOR SUBSETS OF CLL CASES WITH STEREOTYPED B CELL RECEPTORS

EHA Learning Center, Tomas Reigl, 215397

SPONTANEOUS CLINICAL REGRESSION IN CHRONIC LYMPHOCYTIC LEUKEMIA: CLINICAL AND BIOLOGIC FEATURES OF 27 NEW CASES FROM THE EUROPEAN RESEARCH INITIATIVE ON CLL (ERIC) INTERNATIONAL REGISTRY

EHA Learning Center, Ilaria Del Giudice, 215411

A PROGNOSTIC TOOL FOR THE IDENTIFICATION OF EARLY STAGE CHRONIC LYMPHOCYTIC LEUKEMIA PATIENTS AT IMMINENT RISK OF PROGRESSION

EHA Learning Center, Lodovico Terzi di Bergamo, 215412

SURVIVAL CONTINUES TO INCREASE IN CHRONIC LYMPHOCYTIC LEUKEMIA: A POPULATION-BASED ANALYSIS AMONG 19,131 PATIENTS DIAGNOSED IN THE NETHERLANDS BETWEEN 1989 AND 2015

EHA Learning Center, Lina van der Straten, 215413

OPTIMAL TIME POINT FOR BCR-ABL1 KD MUTATION ANALYSIS IN CML PATIENTS; BASED ON 2013 ELN GUIDELINE

EHA Learning Center, Young Rok Do, 215427

CLONAL SELECTION DETERMINES RESULTANT DOMINANCE OF TYROSINE KINASE INHIBITOR-RESISTANT CELLS IN CHRONIC MYELOID LEUKAEMIA

EHA Learning Center, Benjamin Leow, 215428

WT1 ANALYSIS IN CHRONIC MYELOID LEUKEMIA (CML) PATIENTS

EHA Learning Center, Sabrina COLUZZI, 215429

IMATINIB STOP STUDY FEASIBLE TO JAPANESE CLINICAL SETTING.

EHA Learning Center, Kensuke Usuki, 215443

THE TARGET UK STUDY: AN EVALUATION OF TYROSINE KINASE INHIBITOR RESPONSE MONITORING PATTERNS AND REAL-WORLD MOLECULAR RESPONSE RATES IN UK PATIENTS WITH CHRONIC MYELOID LEUKAEMIA

EHA Learning Center, Adam Mead, 215444

THE OCCURRENCE AND SURVIVAL OF COLD AGGLUTININ DISEASE IN DENMARK

EHA Learning Center, Sigbjørn Berentsen, 215445

THE REDUCTION OF GRAFT-VERSUS-HOST DISEASE AND TRANSFUSIONAL NEEDS AFTER THE APPLICATION OF MESENCHYMAL STEM CELL THERAPY FOLLOWING ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION

EHA Learning Center, Hajnalka Andrikovics, 215460

IMMUNOGENICITY OF TISAGENLECLEUCEL IN RELAPSED/ REFRACTORY (R/R) B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA (B-ALL) AND DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL) PATIENTS

EHA Learning Center, Theodore Laetsch, 215461

CONSIDERATIONS FOR TISAGENLECLEUCEL DOSING RATIONALE

EHA Learning Center, Rakesh Awasthi, 215462

TELOMERASE TRANSCRIPTS FLOATING IN CANCER-DERIVED EXOSOMES REPROGRAM THE MICRORNA TRANSCRIPTOME PROFILE OF THE RECIPIENT CELLS

EHA Learning Center, Daniela Likonen, 215476

ALTERATIONS IN STROMAL PRECURSOR CELLS IN THE BONE MARROW OF PATIENTS WITH LEUKEMIA IN THE ONSET OF THE DISEASE AND AFTER TREATMENT

EHA Learning Center, Nataliya Petinati, 215477

LYMPHOPENIA AND RISK OF INFECTIONS AND INFECTION-RELATED DEATH IN DENMARK, 2003-2013: A PROSPECTIVE COHORT STUDY OF 98,344 INDIVIDUALS FROM THE GENERAL POPULATION

EHA Learning Center, Marie Warny, 215478

IBRUTINIB SHOWS PROLONGED PROGRESSION-FREE SURVIVAL IN SYMPTOMATIC, PREVIOUSLY TREATED PATIENTS WITH MYD88 MUTATED WALDENSTROM'S MACROGLOBULINEMIA: LONG-TERM FOLLOW-UP OF PIVOTAL TRIAL (NCT01614821).

EHA Learning Center, Steven Treon, 215492

IMPROVED DEPTH OF RESPONSE WITH INCREASED FOLLOW-UP FOR PATIENTS (PTS) WITH WALDENSTRÖM MACROGLOBULINEMIA (WM) TREATED WITH BRUTON’S TYROSINE KINASE (BTK) INHIBITOR ZANUBRUTINIB

EHA Learning Center, Judith Trotman, 215493

CHARACTERIZATION OF MALT LYMPHOMA WITH T(11;18): LONG-TERM FOLLOW-UP

EHA Learning Center, Kosuke Toyoda, 215494

COLONIZATION WITH MULTIDRUG-RESISTANT BACTERIA (MDRB) IS ASSOCIATED WITH COMPLICATIONS AND POOR OUTCOME AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION (HSCT)

EHA Learning Center, Chiara Maria DELLACASA, 215509

ANTIBIOTICS CAN SAFELY BE DISCONTINUED IN NEUTROPENIC HEMATOLOGY PATIENTS: A PROSPECTIVE COHORT

EHA Learning Center, Zoe Van de Wyngaert, 215510

RISK OF INFECTIOUS COMPLICATIONS IN PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA IN THE ERA OF NOVEL THERAPIES: A RETROSPECTIVE SINGLE INSTITUTION EXPERIENCE

EHA Learning Center, Francesco Autore, 215511

HEMATOPOIETIC IMPROVEMENT AFTER DEFERASIROX TREATMENT IN A CHILD WITH APLASTIC ANEMIA

EHA Learning Center, Gizem Ersoy, 215526

TREATMENT WITH FERRIC CARBOXYMALTOSE FOR SEVERE IRON DEFICIENCY ANEMIA IN STABLE NOT ACTIVELY BLEEDING PATIENTS IN THE EMERGENCY DEPARTMENT

EHA Learning Center, Irene Motta, 215527

IRON DEFICIENCY ANAEMIA – ZINC PROTOPORPHYRIN, A SIMPLE, FAST, INEXPENSIVE DIAGNOSTIC METHOD

EHA Learning Center, João Gomes, 215528

EXPRESSION LEVEL OF SPECIFIC MIRNAS BEFORE AZACITIDINE THERAPY INITIATION MAY PREDICT FUTURE EFFICACY OF THE TREATMENT IN MYELODYSPLASTIC SYNDROMES AND ACUTE MYELOID LEUKEMIA

EHA Learning Center, Michaela Dostalova Merkerova, 215542

MULTICENTRIC VALIDATION OF THE “MONOCYTE ASSAY” FOR CHRONIC MYELOMONOCYTIC LEUKEMIA DIAGNOSIS BY FLOW CYTOMETRY

EHA Learning Center, Orianne Wagner-Ballon, 215543

CHARACTERIZATION AND DIFFERENTIAL EFFECTS OF MESENCHYMAL STROMAL CELL-DERIVED EXTRACELLULAR VESICLES IN PATIENTS WITH MYELODYSPLASTIC SYNDROMES

EHA Learning Center, Manja Wobus, 215544

CHRONIC MYELOMONOCYTIC LEUKEMIA TREATED WITH 5-AZACYTIDINE. RESULTS FROM THE HELLENIC 5-AZACYTIDINE REGISTRY.

EHA Learning Center, Panagiotis Diamantopoulos, 215558

OUTCOME OF PATIENTS WITH MYELODYSPLASTIC SYNDROMES AND STABLE DISEASE DURING TREATMENT WITH AZACITIDINE: A REPORT FROM GRUPPO ROMANO MIELODISPLASIE (GROM) AND RETE EMATOLOGICA LOMBARDA (REL).

EHA Learning Center, Luca Maurillo, 215559

PREDICTIVE FACTORS OF OVERALL SURVIVAL AND TREATMENT RESPONSE IN HIGH-RISK OLDER PATIENTS WITH MDS AND CMML UNDER HYPOMETHILATING AGENTS. LATIN-AMERICAN MDS GROUP - GLAM

EHA Learning Center, Marcelo Iastrebner, 215560

GLUTAMINE-DEPENDENCE TARGETING BY ASPARAGINASE SIGNIFICANTLY INCREASES ANTI-MM ACTIVITY OF PROTEASOME INHIBITION

EHA Learning Center, Paola Minetto, 215575

MITOCHONDRIAL ACTIVITY PLAYS A CRITICAL ROLE IN MULTIPLE MYELOMA RESISTANCE

EHA Learning Center, Alejandra Ortiz, 215576

ELOTUZUMAB PROMOTES SELF-ENGAGEMENT OF SLAMF7 BETWEEN NATURAL KILLER AND MULTIPLE MYELOMA CELLS TO ENHANCE CYTOTOXICITY

EHA Learning Center, Michael D. Robbins, 215577

ADDITION OF VORINOSTAT TO LENALIDOMIDE MAINTENANCE IN NEWLY DIAGNOSED MYELOMA DOES NOT IMPROVE OUTCOMES: RESULTS OF THE MYELOMA XI TRIAL

EHA Learning Center, Matthew Jenner, 215591

POMALIDOMIDE + LOW-DOSE DEXAMETHASONE + DARATUMUMAB IN PATIENTS WITH RELAPSED AND/OR REFRACTORY MULTIPLE MYELOMA AFTER LENALIDOMIDE-BASED TREATMENT FAILURE

EHA Learning Center, David S. Siegel, 215592

DOUBLET VS TRIPLET LENALIDOMIDE-CONTAINING REGIMENS FOLLOWED BY MAINTENANCE: SUBGROUP ANALYSIS BY FRAILTY STATUS AFTER A MEDIAN FOLLOW-UP OF 5 YEARS (EMN01 PHASE III STUDY)

EHA Learning Center, Sara Bringhen, 215593

CHARACTERISTICS, TREATMENT PATTERNS, AND SURVIVAL OUTCOMES OF PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM) IN NORTH AMERICA AND EUROPE: FINDINGS FROM THE PREAMBLE STUDY

EHA Learning Center, Ravi Vij, 215607

COMPLETE RESPONSE AND INDUCTION TREATMENT DOES NOT AFFECT SURVIVAL IN MYELOMA PATIENTS RELAPSING WITHIN 18 MONTHS FOLLOWING UP-FRONT HDM-ASCT. A POPULATION-BASED STUDY FROM 1994 TO 2015

EHA Learning Center, Annette Vangsted, 215608

THE MAJORITY OF NEWLY DIAGNOSED MYELOMA PATIENTS DO NOT FULFIL THE INCLUSION CRITERIA IN CLINICAL PHASE III TRIALS

EHA Learning Center, Tobias Klausen, 215623

COMPARISON OF LYMPHOTRACK® MISEQ® ASSAYS AND FLOW CYTOMETRY FOR CLONALITY AND MINIMUM RESIDUAL DISEASE ASSESSMENT IN MULTIPLE MYELOMA

EHA Learning Center, Austin Jacobsen, 215624

LONG-TERM OUTCOMES OF ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION IN PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA

EHA Learning Center, Qaiser Bashir, 215639

THE SCREENING OF PROTEINS SIGNATURES WITH SIGNALING PATHWAY IN POLYCYTHEMIA VERA AND INHIBITION OF PIM ENHANCES JAK2 INHIBITOR SENSITIVITY

EHA Learning Center, Wuhan Hui, 215640

GENDER EFFECT ON PHENOTYPE AND GENOTYPE IN PATIENTS WITH POST-POLYCYTHEMIA VERA AND POST-ESSENTIAL THROMBOCYTHEMIA MYELOFIBROSIS: RESULTS FROM THE MYSEC PROJECT

EHA Learning Center, Daniela Barraco, 215655

TARGETED TREATMENT WITH DIVERSE TYROSINE KINASE INHIBITORS IN PATIENTS WITH PCM1-JAK2, BCR-JAK2 AND ETV6-ABL1 POSITIVE EOSINOPHILIA-ASSOCIATED MYELOID/LYMPHOID NEOPLASMS

EHA Learning Center, Georgia Metzgeroth, 215656

PREGNANCY OUTCOMES IN PATIENTS WITH MYELOPROLIFERATIVE NEOPLASMS – PALG (POLISH ADULT LEUKEMIA GROUP) A RETROSPECTIVE ANALYSIS

EHA Learning Center, Bozena Sokolowska, 215671

SECOND MALIGNANCIES IN HIDROXYUREA AND INTERFERON TREATED PATIENTS

EHA Learning Center, Telma Domingues, 215672

NUCLEOLIN ENHANCED ADRIAMYCIN RESISTANCE VIA THE REGULATION OF BCL-2 EXPRESSION IN CA46 BURKITT’S LYMPHOMA CELLS

EHA Learning Center, Jianda Hu, 215688

DOMINANT CYTOTOXIC NK CELL SUBSET WITHIN CLPD-NK PATIENTS IDENTIFIES A MORE AGGRESSIVE NK CELL PROLIFERATION

EHA Learning Center, Gregorio Barilà, 215689

EVALUATION OF HIT SYNDROME WITH AN AUTOMATED IMMUNOASSAY IN CORRELATION WITH THE 4T SCORE IN CARDIOVASCULAR PATIENTS

EHA Learning Center, Theoni Kanellopoulou, 215705

IMMATURE PLATELET FRACTION AS A MARKER OF THROMBOPOIESIS IN THROMBOCYTOPENIC PATIENTS

EHA Learning Center, David J Camilleri, 215706

IMPACT OF CMV PROPHYLAXIS ON RATES OF REHOSPITALIZATION IN ADULT CMV SEROPOSITIVE ALLOGENEIC HSCT RECIPIENT: EXPERIENCE FROM THE LETERMOVIR PHASE 3 CLINICAL TRIAL

EHA Learning Center, Jonathan SCHELFHOUT, 215722

QUALITY OF LIFE IN PATIENTS WITH RARE HEREDITARY HEMOLYTIC ANEMIA, THE IMPORTANCE OF SOCIAL SUPPORT

EHA Learning Center, Stephanie van Straaten, 215723

HEME-INDUCIBLE LIPID OXIDATION PATTERN SUPPORTS MONITORING OF CELL-FREE HEMOGLOBIN ACTIVITY IN PATIENTS WITH SICKLE CELL DISEASE.

EHA Learning Center, Jeremy Deuel, 215738

COMPLEMENT ACTIVATION IN HOMOZYGOUS SICKLE CELL DISEASE PATIENTS IS MODULATED BY HYDROXYUREA

EHA Learning Center, Lubka Roumenina, 215739

ASSOCIATION OF SOCIO-ECONOMIC FACTORS WITH SURVIVAL OF PATIENTS WHO EXPERIENCE SEVERE CLASSIC ACUTE GVHD AFTER ALLO-HSCT. A RETROSPECTIVE STUDY BY THE TRANSPLANT COMPLICATIONS WORKING PARTY, EBMT

EHA Learning Center, Andrzej Frankiewicz, 215755

COMPARISON OF REDUCED-INTENSITY CONDITIONING REGIMENS IN PATIENTS WITH ACUTE LYMPHOBLASTIC LEUKEMIA > 45 YEARS UNDERGOING ALLOGENEIC STEM CELL TRANSPLANTATION – A RETROSPECTIVE STUDY BY THE ALWP/EBMT

EHA Learning Center, Zinaida Peric, 215756

PROGNOSTICATION OF CHRONIC GRAFT VERSUS HOST DISEASE: THE IMPACT OF IMMUNE RECONSTITUTION.

EHA Learning Center, Fabio Serpenti, 215771

UTILIZATION AND OUTCOMES OF FERTILITY PRESERVATION TECHNIQUES IN WOMEN UNDERGOING ALLOGENIC HEMATOPOIETIC CELL TRANSPLANT

EHA Learning Center, Alexandra Higgins, 215772

SELECTIVE INHIBITION OF OXIDATIVE PHOSPHORYLATION PREVENTS LETHAL GRAFT-VERSUS-HOST DISEASE WHILE MAINTAINING ANTITUMOR IMMUNITY

EHA Learning Center, Zachariah McIver, 215787

AN UNBALANCED MONOCYTE MACROPHAGE POLARIZATION IN THE BONE MARROW MICROENVIRONMENT MAY CAUSE THE OCCURRENCE OF POOR GRAFT FUNCTION AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION

EHA Learning Center, Hong-Yan Zhao, 215788

COMMON LINK BETWEEN BONE AND HEART HEALTH IN THALASSEMIA MAJOR.

EHA Learning Center, Alessia Pepe, 215803

CEREBRAL IRON OVERLOAD IN BETA THALASSEMIA: DOES IT REALLY MATTER?

EHA Learning Center, Immacolata Tartaglione, 215805

IMMATURE PLATELET FRACTION: A USEFUL MARKER FOR IDENTIFYING THE CAUSE OF THROMBOCYTOPENIA AND PREDICTING PLATELET RECOVERY

EHA Learning Center, Eunyup Lee, 215820

PLATELETPHERESIS-ASSOCIATED LYMPHOPENIA IN FREQUENT PLATELET DONORS

EHA Learning Center, John Gansner, 215821

ENHANCED BONE MARROW HOMING OF NATURAL KILLER CELLS FOLLOWING MRNA TRANSFECTION WITH GAIN-OF-FUNCTION CXCR4

EHA Learning Center, Emily Levy, 215900

INTERLEUKIN-15-CULTURED DENDRITIC CELLS ENHANCE ANTI-TUMOR GAMMA DELTA T CELL FUNCTIONS THROUGH IL-15 SECRETION

EHA Learning Center, Heleen Van Acker, 215901

LABORATORY CHARACTERIZATION OF PATIENTS WITH (SUSPECTED) INHERITED PLATELET DISORDERS: RESULTS FROM THE ‘THROMBOCYTOPATHY IN THE NETHERLANDS’ STUDY

EHA Learning Center, Maaike Blaauwgeers, 215916

A DECREASED PLATELET-TO-LYMPHOCYTE RATIO IS ASSOCIATED WITH A LOW PLATELETCRIT IN PRE-DIABETES

EHA Learning Center, Bongani Nkambule, 215917